Attached files
| file | filename |
|---|---|
| EX-99.4 - EX-99.4 - MADRIGAL PHARMACEUTICALS, INC. | a16-17890_1ex99d4.htm |
| EX-99.3 - EX-99.3 - MADRIGAL PHARMACEUTICALS, INC. | a16-17890_1ex99d3.htm |
| EX-99.2 - EX-99.2 - MADRIGAL PHARMACEUTICALS, INC. | a16-17890_1ex99d2.htm |
| EX-99.1 - EX-99.1 - MADRIGAL PHARMACEUTICALS, INC. | a16-17890_1ex99d1.htm |
| 8-K/A - 8-K/A - MADRIGAL PHARMACEUTICALS, INC. | a16-17890_18ka.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements on Form S-3 (Nos. 333-187242 and 333-206135) and on Form S-8 (Nos. 333-141903, 333-152824, 333-173862, 333-181117, 333-187243, 333-194477, 333-202680, 333-206128 and 333-212615) of our report dated April 12, 2016, relating to the Madrigal Pharmaceuticals, Inc., (“Private Madrigal”), financial statements as of December 31, 2015 and for each of the years in the two-year period then ended, which includes an explanatory paragraph as to the Company’s ability to continue as going concern, included in this Amendment No. 1 to Current Report on Form 8-K.
|
/s/ Friedman LLP |
|
East Hanover, New Jersey |
|
September 2, 2016 |